Hereditary Ovarian Cancer Overview

Genes Associated with Ovarian Cancer


Several Genes Are Associated with Ovarian Cancer

Myriad myRisk® provides insight on other genes that should be considered in order to create an accurate care plan.

5% - 6% of Ovarian Cancers Have Mutations in Genes outside of BRCA1 and BRCA21

In a study 3,088 patients with ovarian cancer, 35% of the pathogenic cancer-associated mutations were identified in genes other than BRCA1 and BRCA2 2

65% BRCA1/2 / 35% Other Mutations

"Advantages of cancer gene panels include decreased cost and improved efficiency of cancer genetic testing by decreasing the time involved, number of patient visits, and number of tests sent. A negative genetic test is more reassuring at eliminating the likelihood of inherited risk when all known genes for that phenotype have been assayed."1

A Multigene Panel Testing Approach Will Allow You to Create a Comprehensive Care Plan

Gaining an accurate understanding of your patient's hereditary cancer status at the time of diagnosis will allow you to determine a comprehensive care plan.

Patient Case Future Cancer Risks* Care Plan Considerations
  • 67-year-old female with Stage III ovarian cancer and no family history of cancer
  • Hereditary cancer status: MSH2-positive
  • Colorectal cancer: up to 82%
  • Gastric cancer: up to 13%
  • Small bowel cancer: up to 6%
*The risks listed above do not represent a comprehensive list of the cancer risks associated with an MSH2 mutation.
Based on this patient's MSH2-positive status, consider the following:
  • Colonoscopy (every 1 to 2 years)
  • Upper endoscopy (every 3 to 5 years)

More information on Myriad myRisk®

Myriad myRisk® has not been reviewed or approved by the FDA.
  • 1 SGO Clinical Practice Statement Next Generation Cancer Gene Panels Versus Gene by Gene Testing. March, 2014
  • 2 Langer LR, Evans B, Saam J, Wenstrup Rj. The Genetic Basis of Ovarian Cancer. Identifying Hereditary Ovarian Cancer Using a 25-gene Panel. Presented at: SGO Annual Meeting on Women's Cancer; March 2015; Chicago, IL.

Myriad, the Myriad logo, MyriadPro, the MyriadPro logo, Myriad myRisk Hereditary Cancer, the Myriad myRisk Hereditary Cancer logo, Myriad myPath Melanoma, the Myriad myPath Melanoma logo, Myriad myPlan Lung Cancer, the Myriad myPlan Lung Cancer logo, BRACAnalysis, the BRACAnalysis logo, COLARIS, the COLARIS logo, COLARIS AP, the COLARIS AP logo, MELARIS, the MELARIS logo, PANEXIA, the PANEXIA logo, Prolaris, the Prolaris logo, ResultsNow, the ResultsNow logo, Myriad Promise, and the Myriad Promise logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.